Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS)
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND: To examine patterns of intravenous (IV) iron use across 12 countries from 1999 to 2011. METHODS: Trends in iron use are described among 32 192 hemodialysis (HD) patients in the Dialysis Outcomes and Practice Patterns Study. Adjusted associations of IV iron dose with serum ferritin and transferrin saturation (TSAT) values were also studied. RESULTS: IV iron was administered to 50% of patients over 4 months in 1999, increasing to 71% during 2009-11, with increasing use in most countries. Among patients receiving IV iron, the mean monthly dose increased from 232 ± 167 to 281 ± 211 mg. Most countries used 3 to 4 doses/month, but Canada used about 2 doses/month, Italy increased from 3 to almost 6 doses/month and Germany used 5 to 6 doses/month. The USA and most European countries predominantly used iron sucrose and sodium ferric gluconate. A significant use of iron dextran was limited to Canada and France; iron polymaltose was used in Australia and New Zealand; and Japan used ferric oxide saccharate, chondroitin polysulfate iron complex and cideferron. Ferritin values rose in most countries: 22% of patients had ≥ 800 ng/mL in the recent years of study. TSAT levels increased to a lesser degree over time. Japan had much lower IV iron dosing and ferritin levels, but similar TSAT levels. In adjusted analyses, serum ferritin and TSAT levels increased signifcantly by 14 ng/mL and 0.16%, respectively, for every 100 mg/month higher mean monthly iron dose. CONCLUSIONS: IV iron prescription patterns varied between countries and changed over time from 1999 to 2011. IV iron use and dose increased in most countries, with notable increases in ferritin but not TSAT levels. With rising cumulative IV iron doses, studies of the effects of changing IV iron dosing and other anemia management practices on clinical outcomes should be a high priority.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Correction of anemia with epoetin alfa in chronic kidney disease
Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065485 · Cited by 2,762
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D., Eckardt, K.-U., Feyzi, J. M., Ivanovich, P., Kewalramani, R., Levey, A. S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907845 · Cited by 2,096
Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency
Anker, S. D., Comin Colet, J., Filippatos, G., Willenheimer, R., Dickstein, K., Drexler, H., Lüscher, T. F., Bart, B., Banasiak, W., Niegowska, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0908355 · Cited by 2,083
Besarab, A., Bolton, W. K., Browne, J. K., Egrie, J. C., Nissenson, A. R., Okamoto, D. M., Schwab, S. J., & Goodkin, D. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390903 · Cited by 1,930
Self-citationAssessing Iron Status: Beyond Serum Ferritin and Transferrin Saturation
Wish, J. B. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01490506 · Cited by 556
Intravenous Iron Alone for the Treatment of Anemia in Patients With Chronic Heart Failure
Bolger, A. P., Bartlett, F. R., Penston, H. S., O’Leary, J., Pollock, N., Kaprielian, R., & Chapman, C. M. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.015 · Cited by 292 · cited 1×
“IV iron has also been recently studied for the treatment of iron deficiency and anemia associated with conditions such as inflammatory bowel disease, pregnancy and the post-partum period, heavy uterine bleeding, congestive heart failure, cancer- and chemotherapy-induced anemia, blood donation and bariatric and electiv…”
Background
Cited by
Camaschella, C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1401038 · Cited by 1,678
Intravenous Iron in Patients Undergoing Maintenance Hemodialysis
Macdougall, I. C., White, C., Anker, S. D., Bhandari, S., Farrington, K., Kalra, P. A., McMurray, J. J. V., Murray, H., Tomson, C. R. V., Wheeler, D. C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1810742 · Cited by 502
Macdougall, I. C., Bircher, A. J., Eckardt, K.-U., Obrador, G. T., Pollock, C. A., Stenvinkel, P., Swinkels, D. W., Wanner, C., Weiss, G., Chertow, G. M., et al. (2016) · Kidney International · doi:10.1016/j.kint.2015.10.002 · Cited by 482
Self-citationIatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century
Rostoker, G., Vaziri, N. D., & Fishbane, S. (2016) · Drugs · doi:10.1007/s40265-016-0569-0 · Cited by 71
Niihata, K., Shimizu, S., Tsujimoto, Y., Ikenoue, T., Fukuhara, S., & Fukuma, S. (2018) · Health Science Reports · doi:10.1002/hsr2.89 · Cited by 12
“Bonucchi D et al (4) University Hospital, Modena, Italy Unknown Previous studies Capelli JP (5) Our Lady of Lourdes Medical Center, US Meeting of the quality assessment team at our lady of Lourdes medical center HCFA case mix indicators Coelho AP et al (6) National Commission for Monitoring of Dialysis, Portugal Unkno…”
Background
Metadata
- Authors
- Bailie, G. R., Larkina, M., Goodkin, D. A., Li, Y., Pisoni, R. L., Bieber, B., Mason, N., Tong, L., Locatelli, F., Marshall, M. R., Inaba, M., & Robinson, B. M.
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-09-27
- Volume
- 28
- Issue
- 10
- Pages
- 2570-2579
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W2147671904
- Cited by
- 104
- References
- 6
- FWCI
- 7.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.